Connor Iapoce

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.

Announced on September 24, 2024, the approval marks the second treatment approved by the FDA for Niemann-Pick disease type C within one week.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

The FDA has set a PDUFA target action date of May 22, 2025, for roflumilast foam 0.3% for individuals aged ≥12 with scalp and body psoriasis.

New research establishes a strong causal link between elevated 25(OH)D levels and a reduced risk of anemia.

A new case-control study reported a higher prevalence of precocious puberty in children and adolescents with HS compared with controls.

Obesity and advanced fibrosis were independent predictors of impaired health-related quality of life in people with T2D.

Arimoclomol, in combination with miglustat, is approved to treat neurological symptoms associated with NPC in adults and children aged ≥2 years.

As advancements in valvular technology progress, Nguyen highlights the need for long-term data and multidisciplinary collaboration to improve patient outcomes.

Lp(a) ordering remains low in patients at risk for ASCVD, particularly non-Hispanic Black or Hispanic individuals in socioeconomically disadvantaged neighborhoods.

EDG-7500 was well-tolerated in healthy patients in Phase 1 while achieving gradient relief without LVEF reductions in the Phase 2 CIRRUS-HCM trial.

Ferric carboxymaltose achieved superior outcomes to an oral iron tablet for the treatment of anemia in pregnant women.

The IL-23 inhibitor lowered the risk of uveitis more than TNF-α inhibitors in patients with moderate to severe psoriasis.

Gildeuretinol showed a clinically meaningful reduction in geographic atrophy lesion growth and a favorable safety profile at 24 months in the Phase 3 SAGA trial.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key updates from the European Society of Cardiology (ESC) Congress 2024.

The FDA advises stopping the fezolinetant treatment at the first signs of liver injury to prevent further damage and help restore normal liver function.

Commercial and government-based sources on Google scored the highest in quality, while medical practices scored the lowest, for information on psoriasis.

Nanoscope Therapeutics announced the meeting with the FDA supported the advancement of MCO-010 into Phase 3 for Stargardt disease.

Multiple biomarkers and clinical background factors were linked to improved clinical outcomes after dupilumab therapy for AD.

MYL-1701P showed equivalent efficacy, with comparable safety and immunogenicity, to reference aflibercept in the Phase 3 INSIGHT trial.

The agency's designation was granted to plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome.

Pre-pregnancy overweight and obesity were not linked to an increased prevalence of iron deficiency or anemia during pregnancy in a US population.

A real-world post-authorization safety study identified no new safety signals compared with the phase 2/3 clinical trial of rpFVIII for acquired hemophilia A.

Lifetime statin treatment increased quality-of-life-adjusted survival in men and women aged ≥70 years with and without previous CVD in the United Kingdom.

ATSN-101 was well tolerated 12 months after treatment and demonstrated on average, a 100-fold improvement in vision, with some improved by 10,000-fold.

Nearly 19% of dementia cases were attributable to ≥1 vision impairment in a nationally representative sample of older US adults.

An investigation into basic and instrumental activities of daily living in older female patients found greater reliance in those with anemia.

A systematic review found a higher prevalence of acute pancreatitis in individuals with the HbSS genotype, though a meta-analysis could not be performed.

The August 2024 cardiology month in review highlights critical data from the European Society of Cardiology Congress 24 and the latest updates on finerenone.

Host Veeral Sheth, MD is joined by John Sheets, PhD, the president, CEO, and co-founder of Pantheon Vision, an early research-stage organization working to develop bioengineered solutions to eliminate corneal blindness.